Clinical Trials · NCT00945477
Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- Illinois CancerCare, P.C.
- Enrollment
- 11
- Start date
- Jul 2009
- Locations
- 4 sites, United States
- Primary endpoint
- Response Rate at 12 Weeks